What Is Ipamorelin?

1. How does ipamorelin work?

Ipamorelin activates the ghrelin receptor, a target involved in growth hormone secretion and gastrointestinal function. Its GH-releasing action depends on the body’s hormone-producing machinery. Recombinant HGH supplies growth hormone directly; ipamorelin supplies a signal to release it.

GH acts on tissues and influences production of insulin-like growth factor 1, or IGF-1. These signals help explain the interest in body composition. They do not tell us how much extra muscle a trained adult will gain or whether an injury will heal sooner.

The Raun et al. pharmacology paper identified ipamorelin as a pentapeptide and tested its activity in rat pituitary cells, rats and pigs. “Pentapeptide” means five amino acids. A small molecule can still have effects across several organs; peptide length is not a safety rating.

Its target also differs from the GHRH receptor activated by sermorelin, tesamorelin and CJC-1295. That difference explains the rationale behind combining these compounds, though it does not establish that a combination delivers better results.

2. What do the human ipamorelin studies show?

Two frequently cited human papers measured very different outcomes. Neither was a muscle-building or sleep trial.

The second study concerned postoperative ileus, the temporary loss of normal gut movement after surgery. A numerical gap between groups is not sufficient to establish treatment efficacy. Its result also cannot tell a healthy lifter what to expect from a subcutaneous injection.

For a physique claim, the missing experiment would measure muscle or fat over time against a suitable comparison group. For a recovery claim, it would measure return of strength, training capacity or injury function. A blood hormone curve answers neither question.

3. Does “selective” mean no cortisol, prolactin or side effects?

In Raun and colleagues’ 1998 experiments, researchers tested hormone selectivity in pigs. Ipamorelin’s ACTH and cortisol responses did not differ significantly from those after GHRH stimulation, even at high experimental doses. GHRP-2 and GHRP-6 increased those hormones under the tested conditions.

ACTH signals the adrenal glands to produce cortisol. That makes the finding relevant to hormone selectivity. It does not demonstrate that ipamorelin lowers stress or treats high cortisol in humans.

The same experiments found no effect on prolactin, FSH, LH or TSH from any of the tested secretagogues. Presenting unchanged prolactin as a unique advantage of ipamorelin would overstate that comparison.

Long-term human use, different formulations and stacks introduce questions the animal experiments did not test. “Selective” cannot substitute for measured rates of glucose problems, fluid retention or other adverse effects.

4. Ipamorelin for muscle growth, fat loss and appetite

There is no dependable human effect size to attach to ipamorelin: no established kilograms of muscle gained, percentage of belly fat lost or improvement in strength. The hormone-response study provides evidence of biological activity without measuring those outcomes.

Animal body-composition results also complicate the fat-loss story. In Lall et al.’s 2001 mouse study, ipamorelin increased fat-pad weight relative to body weight in both GH-deficient and GH-intact mice. Shorter experiments also found increased relative body fat in GH-intact mice treated with secretagogues. The authors reported increased food intake with secretagogue treatment and proposed GH-independent mechanisms for fat gain.

That does not prove ipamorelin makes humans gain fat. It does show why “more GH means less fat” is an inadequate prediction. Claims that ipamorelin never increases hunger also need human appetite data.

For someone using semaglutide or tirzepatide, adding ipamorelin has not been shown by these trials to preserve muscle during weight loss. Nor does the bowel-surgery study establish a treatment for GLP-1-related slow gastric emptying. Both would require separate combination studies.

5. Sleep, recovery and time to results

A GH pulse is not a sleep-stage measurement. The cited human trials did not establish more deep sleep, fewer awakenings or better daytime function. A wearable improvement after starting a stack cannot identify which ingredient contributed, especially if bedtime, alcohol intake or training load changed too.

The same problem applies to workout recovery. Feeling less sore can be useful to record, but it is different from recovering force production or healing a tendon. A claim that ipamorelin accelerates injury repair needs human functional outcomes.

There is also no validated timeline for visible results. An acute hormonal response does not establish that sleep improves within days or body composition changes within eight weeks. Before-and-after photos leave unanswered how calories, resistance training and other drugs changed during that period.

Longevity claims go further still. The studies here did not measure lifespan or prevention of age-related disease. Raising a growth-related marker cannot establish either outcome.

6. CJC-1295 and ipamorelin stacks

CJC-1295 and ipamorelin activate different receptors involved in GH release. This gives researchers a reason to investigate combined stimulation. The individual-compound trials do not establish the benefit of a commercial blend, its ideal ratio or its long-term safety.

The CJC name needs checking too. Teichman and colleagues’ human study tested long-acting CJC-1295 and estimated a half-life of 5.8–8.1 days. Products marketed as “CJC-1295 no DAC,” often called modified GRF(1–29), lack the albumin-binding modification responsible for prolonged exposure. The DAC trial cannot supply results for a no-DAC/ipamorelin blend.

Tesamorelin’s indication is defined in the Egrifta WR prescribing information. Combining it with ipamorelin would need evidence beyond that label. A testimonial involving several peptides cannot separate their effects or identify which caused a new symptom.

7. Ipamorelin half-life, dosage and cycles

Gobburu and colleagues studied intravenous infusions. The reported two-hour half-life describes declining peptide concentration after that route. It is separate from the GH peak and from the time needed for any physical adaptation.

For subcutaneous, nasal or oral products, absorption and formulation introduce additional variables. A half-life graph can illustrate an assumed decay rate; it cannot establish a safe injection interval or predict an individual’s hormone response.

No validated enhancement dose, bedtime schedule, fasting window or cycle length follows from these trials. The surgical study used IV treatment for up to seven days. Converting that hospital experiment into a repeated home-injection regimen would add assumptions about route, population and duration.

Similarly, a calculator can convert a stated concentration into volume without establishing whether the underlying dose is appropriate. Accurate arithmetic cannot validate the clinical premise of a protocol.

8. Ipamorelin side effects and safety gaps

The Beck trial reported treatment-emergent adverse events in 87.5% of the ipamorelin group and 94.8% of the placebo group. These were patients recovering from bowel surgery; those percentages include events after treatment began, regardless of whether treatment caused them. They should not be presented as complication rates for healthy users.

The authors described short-term treatment as well tolerated. The FDA’s 2024 review also discussed two deaths in the IV study and stated that their relationship to ipamorelin was unclear. That uncertainty supports neither blaming the drug for the deaths nor claiming the trial proves long-term safety.

There are broader GH-pathway concerns. The tesamorelin label addresses glucose intolerance, fluid retention and malignancy-related precautions. These are reasons to assess hormone stimulation carefully, not measured ipamorelin event rates. Human evidence cannot currently quantify ipamorelin’s long-term cancer risk.

FDA’s current safety page separately flags potential immune reactions from peptide aggregates or impurities and insufficient safety information for certain injectable routes. Molecular selectivity does not resolve contamination or formulation problems. A purity percentage alone cannot establish the sterility or dose accuracy of a finished injection.

9. FDA status, tested sport and interpreting your own data

Ipamorelin has no FDA-approved use. The FDA review evaluated the free base and acetate forms as distinct bulk substances. “Acetate” identifies a salt form; it does not mean the product has been approved.

FDA also explains that compounded drugs are not FDA-approved. A change in a compounding category would not, by itself, establish efficacy for bodybuilding or FDA approval of a finished drug. Regulatory information here was checked on September 21, 2026.

For tested athletes, WADA’s 2026 Prohibited List names ipamorelin in section S2.2.4. It is prohibited both in and out of competition.

If you are discussing prior or current use with a clinician, bring the exact product and formulation, other medications, dated laboratory results and symptoms. A tracking record is more interpretable when it also includes changes in calorie intake, training and sleep schedule. Higher IGF-1, a smaller waist and a stronger squat are different observations; record each separately rather than treating one as proof of the others.

10. Ipamorelin FAQ

• What is ipamorelin used for?

  Researchers have investigated ipamorelin for growth hormone release and recovery of gut function after surgery. It is marketed for physique, sleep and recovery, but dependable benefits for those uses have not been established in controlled human trials.

• Is ipamorelin a steroid or HGH?

  Ipamorelin is a synthetic peptide that stimulates GH release. It is neither an anabolic steroid nor recombinant human growth hormone. Those differences describe how it works; they do not establish safety.

• Does ipamorelin build muscle or burn belly fat?

  Human trials do not provide a reliable estimate of muscle gained or fat lost. A mouse experiment found increased adiposity, which cautions against assuming that GH release guarantees fat loss; it cannot predict a human user's result.

• Does ipamorelin improve deep sleep?

  A dependable deep-sleep benefit has not been established. Measuring a GH pulse is different from measuring sleep stages, insomnia symptoms or next-day function.

• Does ipamorelin increase hunger?

  Its effect on appetite in healthy human users is not well quantified. Animal findings give reason to question claims that it is always appetite-neutral. Ghrelin-receptor activity alone cannot predict how hungry an individual will feel.

• What is ipamorelin's half-life?

  A 1999 human study estimated a terminal half-life of about two hours after intravenous infusion. Route and formulation matter, so that estimate should not be treated as a validated subcutaneous dosing interval.

• What is the best ipamorelin dosage or cycle?

  No validated enhancement dose, cycle length, fasting window or bedtime schedule has been established. Experimental intravenous regimens do not establish a protocol for self-administered subcutaneous products.

• Is CJC-1295 with ipamorelin better than ipamorelin alone?

  They stimulate GH through different receptors, which gives a rationale for research. The individual-compound studies do not establish superior muscle, sleep or recovery outcomes from the combination, or an effective blend ratio.

• Does ipamorelin raise cortisol or prolactin?

  The original selectivity experiments were conducted in swine. Their hormone findings do not establish what happens during long-term human use or in combinations with other peptides.

• Does ipamorelin cause cancer?

  Human studies cannot quantify its long-term cancer risk. GH and IGF-1 participate in growth signaling, but that mechanism cannot establish either that ipamorelin causes cancer or that it is safe for someone with a cancer history.

• Is ipamorelin FDA-approved or allowed in tested sport?

  Ipamorelin has no FDA-approved use. WADA's 2026 Prohibited List names it among growth hormone secretagogues prohibited both in and out of competition.

11. Sources